COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Equivalence of Complex Drug Products: Scientific and Regulatory Challenges

Missed the NYAS meeting on “Equivalence of Complex Drug Products: Scientific and Regulatory Challenges”? The academy has just published an e-briefing from the meeting. Here you will be able to find notes from the meeting, as well as videos of select presentations. You can also find links to related publications and websites.

The meeting was co-organized by the Non Biological Complex Drugs Working Group, the Nanotechnology Characterization Laboratory (NCL), and the New York Academy of Sciences, and took place November 9, 2016. The conference brought experts from around the world to discuss approaches for complex drug development and regulation, challenges in the assessment of complex drug equivalence, and differences and commonalities in the behavior of biological and non-biological complex drug families.